Nivolumab (Nivo) vs investigator’s choice (IC) for platinum-refractory (PR) recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN; Checkmate 141): Outcomes in first-line ...
The study, published in Lancet Oncology, has found that nivolumab reduced the rate of clinically meaningful deterioration compared with investigator’s choice among platinum-refractory patients being ...
NEW YORK — The OS benefit observed with nivolumab compared with investigator’s choice of single-agent chemotherapy for patients with recurrent or metastatic head and neck squamous cell carcinoma who ...
Bristol-Myers Squibb Company announced two-year overall survival (OS) data from CheckMate -141, a phase 3 open-label, randomized trial evaluating Opdivo (nivolumab) compared with investigator’s choice ...
Opdivo reduced death risk by 30% and doubled one-year survival rates in head and neck cancer patients post-chemotherapy. The CheckMate-141 study established a new standard of care with fewer grade 3/4 ...
Bristol-Myers Squibb’s (BMY) Opdivo has impressed in numerous tumor types, and now looks set to add head and neck cancer to its conquests based on stunning survival data from the Checkmate-141 study ...
The FDA granted Opdivo (nivolumab) a breakthrough therapy designation to treat certain patients with head and neck cancer. After an open-label phase 3 study, CheckMate-141, Opdivo (nivolumab) was ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback